Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 17/20 | 0.75 |
| ▸ | CTSD | P07339 | 1/20 | 0.48 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4813038 | 0.91 | BACE1 (0.62) | BACE1 | |
| SCHEMBL4810071 | 0.90 | BACE1 (0.62) | BACE1CTSDBACE2MAPT | |
| SCHEMBL4804685 | 0.86 | BACE1 (1.00) | BACE1CTSDBACE2 | |
| SCHEMBL4812110 | 0.83 | BACE1 (0.56) | BACE1 | |
| SCHEMBL4806389 | 0.82 | BACE1 (0.75) | BACE1MAPT | |
| SCHEMBL4813230 | 0.81 | BACE1 (0.50) | BACE1RAB9A | |
| SCHEMBL4816021 | 0.79 | BACE1 (0.51) | BACE1 | |
| SCHEMBL4811686 | 0.79 | BACE1 (0.55) | BACE1 | |
| SCHEMBL4809434 | 0.78 | BACE1 (0.84) | BACE1CTSDBACE2MAOAMAPT | |
| SCHEMBL4811510 | 0.77 | BACE1 (0.66) | BACE1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7459567-B2 | Substituted thienyl and furyl acylguanidines and methods of their use as beta-secretase modulators | WYETH (US) | 2008-12-02 | — | — | US | disclosed |
| WO-2006088694-A1 | SUBSTITUTED THIENYL AND FURYL ACYLGUANIDINES AS β-SECRETASE MODULATORS | WYETH (US) | 2006-08-24 | — | — | WO | disclosed |
| US-20060183792-A1 | Substituted thienyl and furyl acylguanidines and methods of their use as beta-secretase modulators | WYETH (US) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183792-A1 | Substituted thienyl and furyl acylguanidines and methods of their use as beta-secretase modulators | BACE1, BACE2, PSEN1 | BACE1 1/4885CTSD 146/4885BACE2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.